Clinical Profile of Single-Agent Oprozomib in Patients (Pts) with Multiple Myeloma (MM): Updated Results from a Multicenter, Open-Label, Dose Escalation Phase 1b/2 Study

被引：2
|
作者：
Vij, Ravi [1 ]
Savona, Michael [2 ]
Siegel, David S. [3 ]
Kaufman, Jonathan L. [4 ]
Badros, Ashraf [5 ]
Ghobrial, Irene M. [6 ]
Paner, Agne [7 ]
Jagannath, Sundar [8 ]
Jakubowiak, Andrzej [9 ]
Mikhael, Joseph R. [10 ]
Kapoor, Prashant [11 ]
Neuman, Linda L. [12 ]
Lee, Ju RueyJiuan [13 ]
Berdeja, Jesus G. [14 ]
机构：
[1] Washington Univ, Sch Med, St Louis, MO USA
[2] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA
[3] Hackensack Univ, Med Ctr, Hackensack, NJ USA
[4] Emory Univ, Atlanta, GA 30322 USA
[5] Univ Maryland, Baltimore, MD 21201 USA
[6] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA
[7] Rush Univ, Med Ctr, Chicago, IL 60612 USA
[8] Mt Sinai Hosp, New York, NY 10029 USA
[9] Univ Chicago Med, Chicago, IL USA
[10] Mayo Clin Arizona, Scottsdale, AZ USA
[11] Mayo Clin, Rochester, MN USA
[12] Onyx Pharmaceut Inc, Redwood City, CA USA
[13] Onyx Pharmaceut Inc, San Francisco, CA USA
[14] Sarah Cannon Res Inst, Nashville, TN USA
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [41] Long-term safety and efficacy of single-agent lbrutinib in patients with relapsed or refractory mantle cell lymphoma: Updated results of an international, multicenter, open-label phase 2 study
    Dreyling, M.
    Wang, M. L.
    Rule, S.
    Martin, P.
    Goy, A.
    Auer, R.
    Kahl, B. S.
    Jurczak, W.
    Advani, R. H.
    Romaguera, J. E.
    Williams, M. E.
    Barrientos, J. C.
    Chmielowska, E.
    Radford, J.
    Stilgenbauer, S.
    Jedrzejczak, W. W.
    Johnson, P.
    Spurgeon, S. E.
    Zhang, L.
    Baher, L.
    Cheng, M.
    Beaupre, D. M.
    Blum, K. A.
    Oncology Research and Treatment, 2015, 38 : 18 - 19
  • [42] Results of PX-171-003-A1, An Open-Label, Single-Arm, Phase 2 (Ph 2) Study of Carfilzomib (CFZ) In Patients (pts) with Relapsed and Refractory Multiple Myeloma (MM)
    Samuel, David
    Martin, Thomas
    Wang, Michael
    Vij, Ravi
    Jakubowiak, Andrzej J.
    Jagannath, Sundar
    Lonial, Sagar
    Kukreti, Vishal
    Bahlis, Nizar J.
    Alsina, Melissa
    Chanan-Khan, Asher A.
    Somlo, George
    Buadi, Francis
    Reu, Frederic J.
    Zonder, Jeffrey A.
    Song, Kevin
    Stadtmauer, Edward
    Wong, Alvin F.
    Vallone, Marcy
    Chang, Yu-Lin
    Kauffman, Michael
    Orlowski, Robert Z.
    Stewart, A. Keith
    Singhal, Seema B.
    BLOOD, 2010, 116 (21) : 433 - 433
  • [43] Phase 1, multicenter, open-label study of single-agent bispecific antibody T-cell engager GBR 1342 in relapsed/refractory multiple myeloma.
    Richter, Joshua Ryan
    Wermke, Martin
    Kauh, John S.
    Back, Jonathan
    Salhi, Yacine
    Reddy, Venkateshwar
    Bayever, Eliel
    Landgren, Carl Ola
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05)
  • [44] Phase 1, multicenter, open-label study of single-agent bispecific antibody t-cell engager GBR 1342 in relapsed/refractory multiple myeloma.
    Richter, Joshua Ryan
    Landgren, Carl Ola
    Kauh, John S.
    Back, Jonathan
    Salhi, Yacine
    Reddy, Venkateshwar
    Bayever, Eliel
    Berdeja, Jesus G.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [45] Daratumumab (DARA) in Combination with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) in Patients with Newly Diagnosed Multiple Myeloma (MMY1001): Updated Results from an Open-Label, Phase 1b Study
    Chari, Ajai
    Usmani, Saad Z.
    Krishnan, Amrita
    Lonial, Sagar
    Comenzo, Raymond
    Wu, Kaida
    Wang, Jianping
    Doshi, Parul
    Weiss, Brendan M.
    Schecter, Jordan
    Jakubowiak, Andrzej J.
    BLOOD, 2017, 130
  • [46] A phase 1, open-label, dose escalation study of AMG 337 in Asian patients (pts) with advanced solid tumors
    Yasui, Hirofumi
    Amore, Benny
    Jiang, Yizhou
    Murugappan, Swaminathan
    Doi, Toshihiko
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [47] Phase II open-label study of recombinant circularly permuted TRAIL as a single-agent treatment for relapsed or refractory multiple myeloma
    Leng, Yun
    Qiu, Lugui
    Hou, Jian
    Zhao, Yaozhong
    Zhang, Xuejun
    Yang, Shifang
    Xi, Hao
    Huang, Zhongxia
    Pan, Ling
    Chen, Wenming
    CHINESE JOURNAL OF CANCER, 2016, 35 : 86
  • [48] OPROZOMIB, POMALIDOMIDE, AND DEXAMETHASONE (OPOMD) IN PATIENTS (PTS) WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM): INITIAL RESULTS OF A PHASE 1B STUDY (NCT01999335)
    Shah, J.
    Niesvizky, R.
    Stadtmauer, E.
    Rifkin, R. M.
    Berenson, J.
    Berdeja, J.
    Sharman, J.
    Lyons, R.
    Klippel, Z.
    Wong, H.
    Chang, Y. L.
    Usmani, S.
    HAEMATOLOGICA, 2016, 101 : 81 - 81
  • [49] An open-label, multicenter, phase 1 study of RP3 as a single agent and in combination with nivolumab in patients (pts) with solid tumors
    Harrington, Kevin Joseph
    Rullan, Antonio
    Deighton, Louise
    Barata, Joao
    Castro, Henry
    Ahlers, Christoph Matthias
    Mcrae, John
    Bommareddy, Praveen
    Coffin, Robert S.
    Middleton, Mark R.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [50] A Phase 2 open-label, multicenter study of single-agent rucaparib in the treatment of patients with relapsed ovarian cancer and a deleterious BRCA mutation
    Shapira-Frommer, R.
    Oza, A.
    Domchek, S. M.
    Balmana, J.
    Patel, M. R.
    Chen, L. M.
    Drew, Y.
    Burris, H. A., III
    Korach, J.
    Flynn, M.
    Bowering, V. L.
    Morgan, M. A.
    Watkins, S. P.
    Simpson, D.
    Goble, S.
    Maloney, L.
    Kristeleit, R.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S545 - S545
12345